We first identified the HCC cell subgroup C16+C18 cell cluster that was sensitive to TCC therapy and determined that the expression level of the SAMD4B gene significantly increased and the expression level of APOA2 significantly decreased. The gene discussed is SAMD4B; the disease is hepatocellular carcinoma.